Last Updated on October 6, 2024 by The Health Master
PLI Schemes for Pharmaceuticals and Medical Devices
India’s Central government reports that the three Production Linked Incentive (PLI) schemes in the pharmaceuticals and medical devices sector have attracted a remarkable investment of Rs. 21,861 crore as of March 2023.
Among the three schemes, the PLI scheme for pharmaceuticals has received the majority of the investments.
These initiatives, launched by the Government of India, aim to bolster domestic manufacturing, achieve self-reliance, and attract significant investments in the sector.
Investments in PLI Schemes:
Pharmaceuticals Scheme:
The PLI scheme for pharmaceuticals has witnessed investments totaling Rs. 18,618.09 crore until March 2023.
With a financial outlay of Rs. 15,000 crore over six years, this scheme has received substantial attention.
For the financial year 2022-23, the Department of Pharmaceuticals has allocated a budget outlay of Rs. 690 crore.
Bulk Drugs Scheme:
The PLI scheme for bulk drugs has attracted investments amounting to Rs. 2,405.09 crore. The scheme’s objective is to enhance domestic production of 41 critical bulk drugs in India.
Out of the 34 notified bulk drugs, 51 projects have been selected, with 22 projects already commissioned.
The incentive rates for fermentation-based products are 20%, while chemical-based products receive 10% for the first four years, gradually tapering over the subsequent two years.
Medical Devices Scheme:
The PLI scheme for medical devices has secured an investment of Rs. 837.23 crore.
With a financial outlay of Rs. 3,420 crore, this initiative aims to establish domestic manufacturing capabilities for high-end medical devices in four target segments:
Four target segments:
- Cancer care/radiotherapy medical devices
- Radiology and imaging medical devices (ionizing & non-ionizing radiation products, nuclear imaging devices)
- Anaesthetics and cardio-respiratory medical devices, including catheters and renal care devices
- All implants, including implantable electronic devices
Medical Devices Manufactured under PLI Scheme:
The medical devices manufactured under the PLI scheme include advanced equipment such as:
- CT scan machines,
- MRI Coils,
- Linear Accelerators (LINAC),
- C-Arms,
- Ultrasonography devices,
- Dialysis machines,
- Intensive care ventilators,
- Knee and hip implants,
- Heart valves,
- Stents, and
- Dialyzers.
Remarkably, some of these high-end medical devices are being domestically manufactured for the first time in India.
The PLI scheme has successfully established an ecosystem to support the domestic manufacturing of these critical medical devices, as stated by the Ministry of Chemicals and Fertilizers.
Conclusion:
India’s PLI schemes for pharmaceuticals, bulk drugs, and medical devices have attracted significant investments, fostering self-reliance and domestic manufacturing capabilities in the sector.
These initiatives align with the government’s vision to boost the country’s healthcare industry, encourage innovation, and ensure access to high-quality medical devices and pharmaceuticals for its citizens.
Procedure to obtain license for manufacturing of Medical Devices
Procedure for registration of Medical Devices: CDSCO
Registration for sale of Medical Devices: Procedure and conditions
Latest Notifications: Medical Devices
Classifications of Medical Devices under the provisions of MDR 2017
Notified Bodies for Medical Devices
Updated list of Notified Bodies for Medical Devices
Updated list of Medical Device Testing Laboratories (MDTLs)
Licensing procedure for manufacturing of Drugs
Procedure to obtain license for manufacturing of Cosmetics
Procedure to obtain license for manufacturing of Homoeopathic Medicines
Procedure to obtain License to Manufacture drugs for testing and analysis purposes
Procedure to obtain license for Commercial Testing Laboratories
Drug alert: 28 out of 1302 samples declared as NSQ in May 2023
DCGI approves first indigenously developed animal-derived Class D Biomedical Device
Action to be taken against Pharmacies offering abnormal discounts: Karnataka
NPPA Guidelines: For change of Manufacturer in Notified Drug Formulations
Pharma Traders Association request time to withdraw recently banned 14 FDCs
IPC: These 5 countries recognize Indian Pharmacopoeia (IP)
394 Product Permissions of 14 banned FDCs to be cancelled: Gujarat
NPPA revised Ceiling price of 15 scheduled formulations: June 2023
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon: